公开(公告)号：US20180305465A1

公开(公告)日：2018-10-25

申请号：US15779325

申请日：2016-11-23

Applicant: AMGEN INC. ,  XENCOR, INC.

Inventor： Jennitte Leann Stevens ,  Mercedesz Balazs ,  Olivier Nolan-Stevaux ,  Gregory Moore ,  John Desjarlais ,  Matthew J. Bernett ,  Seung Y. Chu ,  Rumana Rashid ,  Umesh Muchhal

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/40 ,  A61P35/00

CPC classification number: C07K16/468 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/40 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92

Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.

公开(公告)号：US20240026002A1

公开(公告)日：2024-01-25

申请号：US18452395

申请日：2023-08-18

Applicant: Xencor, Inc.

Inventor： Matthew J. Bernett ,  Gregory Moore ,  John Desjarlais ,  Michael Hedvat ,  Christine Bonzon

IPC: C07K16/28 ,  A61P35/00 ,  A61P37/06

CPC classification number: C07K16/2818 ,  A61P35/00 ,  A61P37/06 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/52 ,  C07K2317/33 ,  C07K2317/31 ,  A61K2039/507

Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.

公开(公告)号：US20230340144A1

公开(公告)日：2023-10-26

申请号：US18172196

申请日：2023-02-21

Applicant: XENCOR, INC.

Inventor： Matthew J. Bernett ,  Seung Yup Chu ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar ,  Erik Weiking Pong ,  John O. Richards ,  Eugene Alexander Zhukovsky

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

公开(公告)号：US20220227867A1

公开(公告)日：2022-07-21

申请号：US17561613

申请日：2021-12-23

Applicant: Xencor, Inc.

Inventor： Matthew J. Bernett ,  John R. Desjarlais ,  Gregory Moore ,  Suzanne Schubbert

IPC: C07K16/28 ,  C07K14/54 ,  C07K14/715 ,  C12N15/63

Abstract: The present invention is directed to novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a ICOS antibody fragment-Fc fusion protein.

公开(公告)号：US11225528B2

公开(公告)日：2022-01-18

申请号：US16354058

申请日：2019-03-14

Applicant: Xencor, Inc.

Inventor： Matthew J. Bernett ,  Gregory Moore ,  John Desjarlais ,  Seung Chu ,  Rumana Rashid ,  Umesh Muchhal ,  Sung-Hyung Lee

IPC: C07K16/30 ,  C07K16/46 ,  C07K16/28 ,  C07K16/40 ,  A61K39/00

Abstract: The present invention is directed to novel heterodimeric antibodies.

公开(公告)号：US11111315B2

公开(公告)日：2021-09-07

申请号：US15945681

申请日：2018-04-04

Applicant: Xencor, Inc.

Inventor： Matthew J. Bernett ,  Gregory Moore ,  John Desjarlais ,  Seung Chu ,  Rumana Rashid ,  Umesh Muchhal ,  Sung-Hyung Lee

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

Abstract: The present invention is directed to novel heterodimeric antibodies.

公开(公告)号：US20210230250A1

公开(公告)日：2021-07-29

申请号：US17231848

申请日：2021-04-15

Applicant: Xencor, Inc.

Inventor： Gregory A. Lazar ,  Matthew J. Bernett

IPC: C07K14/705 ,  C07K19/00 ,  C07K16/46

Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.

公开(公告)号：US09856327B2

公开(公告)日：2018-01-02

申请号：US15186167

申请日：2016-06-17

Applicant: Xencor, Inc.

Inventor： Matthew J. Bernett ,  Gregory Moore ,  John Desjarlais ,  Seung Chu ,  Rumana Rashid ,  Umesh Muchhal ,  Sung-Hyung Lee

IPC: C07K16/00 ,  C07K16/46 ,  C07K16/28 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/468 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/2866 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3061 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention is directed to novel heterodimeric antibodies.

公开(公告)号：US09605061B2

公开(公告)日：2017-03-28

申请号：US14165487

申请日：2014-01-27

Applicant: XENCOR, INC.

Inventor： Gregory A. Lazar ,  Bassil I. Dahiyat ,  Matthew J. Bernett

IPC: C07K16/00 ,  C12P21/08 ,  C07K16/22 ,  C07H21/00 ,  C07K14/00

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07H21/00 ,  C07K16/00 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/94

Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.

公开(公告)号：US20160176969A1

公开(公告)日：2016-06-23

申请号：US14952705

申请日：2015-11-25

Applicant: XENCOR, INC.

Inventor： Matthew J. Bernett ,  Gregory Moore ,  John Desjarlais ,  Seung Chu ,  Sung-Hyung Lee

IPC: C07K16/28 ,  C07K16/40 ,  C07K16/46

CPC classification number: C07K16/2815 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/90 ,  C07K2317/94

Abstract: The invention provides bispecific antibodies that co-engage CD8 (preferably bivalently) and a target tumor antigen.

Abstract translation: 本发明提供了共参与CD8（优选二价））和靶肿瘤抗原的双特异性抗体。